A Novel Nonreciprocal/Reciprocal ALK Translocation Cause ALK plus in NSCLC

被引：0
|
作者：
Chen, Xianguo [1 ]
Xu, Bo [1 ]
Fu, Fangni [2 ]
Cai, Ke [2 ]
Yu, Zhaonan [2 ]
机构：
[1] Zhejiang Univ, Jinhua Hosp, Dept Thorac Surg, Jinhua 330700, Zhejiang, Peoples R China
[2] Hangzhou DA Med Lab, Hangzhou 310030, Peoples R China
来源：
LUNG CANCER | 2021年 / 158卷
关键词：
D O I：
10.1016/j.lungcan.2021.05.020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：162 / 163
页数：2
相关论文
共 50 条
  • [1] Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First -Line Crizotinib-Treated ALK-Rearranged NSCLC
    Zhang, Yongchang
    Zeng, Liang
    Zhou, Chunhua
    Li, Yizhi
    Wu, Lin
    Xia, Chen
    Jiang, Wenjuan
    Hu, Yijuan
    Liao, Dehua
    Xiao, Lili
    Liu, Li
    Yang, Haiyan
    Xiong, Yi
    Guan, Rui
    Lizaso, Analyn
    Mansfield, Aaron S.
    Yang, Nong
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (06) : 1027 - 1036
  • [2] A novel 3 ' truncated ALK cause ALK plus in a patient with minimally invasive adenocarcinoma
    Chen, Jian
    Yu, Zhaonan
    Li, Xinjian
    Xu, Guoying
    Wang, Yue
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (04) : 1005 - 1006
  • [3] MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC
    Fang, Wenfeng
    Gan, Jiadi
    Hong, Shaodong
    Lu, Feng
    Zhang, Li
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) : E148 - E151
  • [4] Brigatinib Effective in ALK plus NSCLC
    Leslie, Mitch
    CANCER DISCOVERY, 2017, 7 (01) : 4 - 5
  • [5] ALK plus NSCLC ALK Inhibitors symbolize Progress in Cancer Medicine
    Kohl, Angelika
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 435 - 435
  • [6] Description of ALK plus NSCLC patient characteristics and ALK testing patterns
    Wakelee, Heather A.
    Sasane, Medha
    Zhang, Jie
    Macalalad, Alexander R.
    Galebach, Philip J.
    Jarvis, John
    Kageletry, Andrew James
    Huang, Qing
    Culver, Kenneth W.
    Wu, Eric Qiong
    Guerin, Annie
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Description of ALK plus NSCLC Patient Characteristics and ALK Testing Patterns
    Wakelee, H. A.
    Sasane, M.
    Zhang, J.
    Macalalad, A. R.
    Galebach, P.
    Jarvis, J.
    Kageleiry, A.
    Huang, Q.
    Culver, K.
    Wu, E. Q.
    Guerin, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S60 - S61
  • [8] ALK plus advanced NSCLC New ALK Inhibitor extends Sequence Options
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (11) : 720 - 720
  • [9] Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK plus NSCLC
    Leal, Ticiana
    Wakelee, Heather
    Infante, Jeffrey
    Blumenschein, George
    Reckamp, Karen
    Carter, Corey
    Waqar, Saiama
    Gockerman, Jon
    Lovly, Christine
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S209 - S210
  • [10] A RETROSPECTIVE COMPABILITY ASSESSMENT OF ALK TRANSLOCATION DIAGNOSIS IN NSCLC
    Yokoi, Takashi
    Kurata, Takayasu
    Torii, Yoshitaro
    Katashiba, Yuichi
    Niki, Maiko
    Sawai, Yusuke
    Nomura, Shosaku
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1287 - S1288
12345